Leaders League Features Dave Marriott as Top Trial Lawyer
July 17, 2024
On June 6, 2024, Cravath partner David R. Marriott was recognized by Leaders League as a leading trial lawyer in the United States. The profile praised Dave’s “uncommon ability to consistently win complex cases of every hue, often against all odds,” as exemplified by his representation of clients including Illumina in its unprecedented antitrust trial victory against the FTC; Amgen in its successful defense against the FTC’s challenge to its $27.8 billion acquisition of Horizon Therapeutics; Louis Dreyfus Company and Imperial Sugar Company in their trial victory over the DOJ; Viatris in its summary judgment win to defeat a securities class action; and photographers Donald Graham and Eric McNatt, who secured favorable SDNY judgments in copyright infringement litigation against appropriation artist Richard Prince and his galleries. The publication deemed his work on the antitrust cases “a string of stunning…victories” in “three of the most significant antitrust cases of the last decade.” Leaders League further remarked that “Marriott never shirks from a challenge, no matter how daunting [the] odds or opposition.”
Related Practices & Industries
- Litigation
- Antitrust
- Appellate
- Class Action Defense
- General Commercial Disputes
- Intellectual Property Litigation
- M&A Litigation
- Securities Litigation
- Trials
- Pro Bono
- Consumer Products and Services
- Financial Services and Insurance
- Healthcare and Life Sciences
- Media and Entertainment
- Technology
- Transportation
People
- Photo
-
-
J.D., 1994, New York University School of Law
-
B.A., 1991, Brigham Young Universitymagna cum laude
- New York
Education
Admitted In
Related News
Deals & Cases
September 02, 2022
Illumina Secures Unprecedented Antitrust Trial Win in FTC’s Challenge to GRAIL Acquisition
On September 1, 2022, Chief Administrative Law Judge D. Michael Chappell of the Federal Trade Commission (“FTC”) ruled in favor of Cravath client Illumina, rejecting the FTC’s challenge to Illumina’s $8 billion acquisition of GRAIL, which closed in August 2021.
Deals & Cases
September 11, 2023
Amgen Successfully Defends Against FTC Challenge, Securing Clearance for its $27.8 Billion Acquisition of Horizon Therapeutics
Cravath represented Amgen, one of the world’s largest biopharmaceutical companies, in successfully defending against a Federal Trade Commission (“FTC”) challenge to Amgen’s pending $27.8 billion acquisition of Horizon Therapeutics (“Horizon”)—securing a consent order on September 1, 2023 that The Wall Street Journal described as “a rare instance” of the FTC “throwing in the towel on litigation.”
Deals & Cases
July 14, 2023
Louis Dreyfus Company and Imperial Sugar Company Win Appellate Victory Over DOJ
On July 13, 2023, a three judge panel for the U.S. Court of Appeals for the Third Circuit ruled in favor of Cravath clients Louis Dreyfus Company LLC (“LDC”) and Imperial Sugar Company (“Imperial Sugar”) and unanimously affirmed an earlier decision by the U.S. District Court for the District of Delaware denying U.S. Department of Justice’s (“DOJ”) request for an injunction to block LDC’s sale of the assets and business of Imperial Sugar to U.S. Sugar.
Deals & Cases
April 07, 2023
Viatris Wins Summary Judgment in Securities Class Action
On Thursday, March 30, 2023, the U.S. District Court for the Southern District of New York granted summary judgment in favor of Cravath client Viatris (formed in 2020 from a combination of Mylan and Pfizer’s Upjohn division). The shareholder class action asserted numerous violations of the federal securities laws, all premised on other allegations related to Mylan’s marketing, pricing and classification of EpiPen as well as alleged conduct concerning generic drug price fixing and market allocation.
